Overview / Abstract: |
Almost 10% of the US population has diabetes, and half are not achieving glycemic goals. GLP-1 receptor agonists (GLP-1 RAs) work by decreasing glucagon secretion in a glucose-dependent manner and by activating the GLP-1 receptor, increasing insulin release in the presence of elevated glucose concentrations. There are common misperceptions about injectable GLP-1 RAs, including an overestimation of patient fears of injection pain, that cause these agents to be under-prescribed. Based on recent clinical-trial data, one GLP-1 RA is approved not only as an adjunct to diet and exercise to improve glycemic control in adults with T2DM, but also to reduce the risk of major cardiovascular events in adults with T2DM and established cardiovascular disease. GLP-1 RAs represent a unique approach to T2DM treatment, with potential benefits extending beyond glucose control and including positive effects on body weight, blood pressure, and beta-cell function. This activity, “Ensuring Optimal Integration of the GLP-1 Receptor Agonists,” will update primary care clinicians on the safety and efficacy data for approved GLP-RAs, review the most recent guideline and expert recommendations for their use, and suggest strategies to overcome barriers to their use in appropriate patients. |
Expiration |
Jan 30, 2021 |
Discipline(s) |
Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.00 |
Accreditation |
ACCME, ANCC, AAFP, AAPA, ABIM MOC, MIPS |
Presenters / Authors / Faculty |
Richard S. Rosenthal, MD |
Activity Specialities / Related Topics |
Primary Care, Family Medicine |
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Novo Nordisk Inc. |
Keywords / Search Terms |
Rockpointe T2DM, GLP-1, Free, CME, MIPS, AAFP credit Free CE CME |